Hypothesis

We hypothesize that the age-related decline in autophagic flux in post-mitotic neurons is primarily driven not by absolute NAD+ depletion, but by the collapse of circadian NAD+ oscillation amplitude — the difference between peak and trough NAD+ levels across the 24-hour cycle. This amplitude decay uncouples the SIRT1-mediated deacetylation of TFEB (transcription factor EB) from its circadian nuclear translocation rhythm, resulting in constitutive cytoplasmic sequestration of TFEB and failure to activate lysosomal biogenesis genes during the physiological autophagy window (late sleep phase).

Mechanistic Rationale

NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, is itself a clock-controlled gene with robust circadian expression peaking during the active phase. In young organisms, this creates a high-amplitude NAD+ oscillation (~2-fold peak-to-trough ratio in murine hypothalamus) that temporally gates SIRT1 activity. SIRT1 deacetylates TFEB at K116 and K274, enabling its nuclear import and transcriptional activation of CLEAR (Coordinated Lysosomal Expression and Regulation) network genes.

With aging, BMAL1 expression declines and NAMPT circadian amplitude dampens, compressing the NAD+ oscillation to <1.3-fold. Critically, mean NAD+ may remain sufficient for basal SIRT1 activity, but the loss of the circadian peak eliminates the temporal window of maximal SIRT1-TFEB activation needed for bulk autophagic clearance. The result: basal autophagy persists but the pulsatile, high-throughput clearance phase is lost — explaining why lipofuscin (the non-degradable residue of incomplete autophagy) accumulates specifically in post-mitotic cells that cannot dilute it through division.

Testable Predictions

1. Primary: In aged (24-month) vs. young (3-month) mouse hippocampal neurons, NAD+ oscillation amplitude (measured by continuous NAD+ biosensor imaging over 48h) will be reduced by ≥50%, while mean NAD+ decreases by only 20-30%.
2. Phase uncoupling: TFEB nuclear localization will lose circadian rhythmicity in aged neurons (cosinor analysis amplitude p>0.05), while young neurons show robust oscillation (p<0.001) with peak nuclear TFEB coinciding with NAD+ peak + 4h phase delay.
3. Amplitude rescue: Timed NMN administration (bolus at ZT12, onset of active phase) in aged mice will restore NAD+ oscillation amplitude without changing 24h mean NAD+, and this will rescue TFEB nuclear rhythmicity and reduce hippocampal lipofuscin by ≥30% over 8 weeks.
4. Flat supplementation fails: Continuous NMN infusion (same total daily dose, delivered evenly) will raise mean NAD+ equivalently but fail to restore oscillation amplitude, TFEB rhythmicity, or lipofuscin clearance — demonstrating that amplitude, not mean level, is the critical variable.
5. SIRT1 dependency: Neuron-specific SIRT1 knockout will abolish the benefit of timed NMN, confirming the SIRT1-TFEB axis as the mechanistic link.
6. Translational correlate: In human CSF samples, the ratio of morning-to-evening NAM (nicotinamide, an NAD+ metabolite) will correlate inversely with CSF lipofuscin-associated autofluorescent biomarkers and positively with cognitive performance in adults >65 years.

Limitations

• Continuous NAD+ measurement in live neurons requires genetically encoded biosensors (e.g., cpVenus-based NAD+ sensors) with limited dynamic range and potential phototoxicity during extended imaging
• Lipofuscin quantification is semi-quantitative and tissue-preparation dependent
• NMN pharmacokinetics differ between bolus and infusion routes beyond timing — absorption kinetics may confound the amplitude vs. mean comparison
• Post-mitotic neuron specificity may not generalize to other long-lived post-mitotic cells (cardiomyocytes, skeletal muscle fibers) where autophagy regulation differs
• Human CSF NAM circadian sampling requires indwelling lumbar catheters, limiting feasibility
• Clock gene disruption in aging is multifactorial — isolating NAMPT-NAD+ amplitude from broader circadian decay requires careful genetic controls

Significance

This hypothesis reframes the NAD+-aging-autophagy connection from a simple depletion model to a chronobiological phase-coupling problem. If validated, it implies that the timing of NAD+ precursor supplementation matters more than the dose — a finding with immediate translational implications for the design of NMN/NR clinical trials in neurodegeneration. Current trials using fixed daily dosing may be systematically missing the therapeutic window. More broadly, it suggests that restoring circadian amplitude in key metabolic oscillators, rather than simply elevating their mean levels, should be a central strategy in geroscience interventions.